Evidence map›Paper›PMID 30297199›Full record

Trial reportNutrition, metabolism, and cardiovascular diseases : NMCD2018

Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health.

E R Miranda, K N Z Fuller, R K Perkins, C M Kroeger, J F Trepanowski, K A Varady, J M Haus

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition, metabolism, and cardiovascular diseases : NMCD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00960505 (Alternate Day Fasting for Weight Loss, Weight Maintenance and Cardio-protection), which is not on this map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00960505 nacompletednot on this map

Alternate Day Fasting for Weight Loss, Weight Maintenance and Cardio-protection

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2010 to 2015Enrolled100ConditionsCoronary Heart Disease, Obesity, Weight LossArmsAlternate day fasting, Calorie restriction, Control diet
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Receptor for the Advanced Glycation End Products (International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. Advanced Glycation End Products and Inflammatory Cytokine Profiles in Maintenance Hemodialysis Patients After the Ingestion of a Protein-Dense Meal.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2023
    Article
  15. Article
  16. Does AGE-RAGE Stress Play a Role in the Development of Coronary Artery Disease in Obesity?The International journal of angiology : official publication of the International College of Angiology, Inc · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

E R MirandaSchool of Kinesiology, University of Michigan, Ann Arbor, MI, United States.
K N Z FullerKinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, United States.
R K PerkinsSchool of Kinesiology, University of Michigan, Ann Arbor, MI, United States.
C M KroegerDepartment of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, United States.
J F TrepanowskiKinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, United States.
K A VaradyKinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, United States.
J M HausSchool of Kinesiology, University of Michigan, Ann Arbor, MI, United States. Electronic address: jmhaus@umich.edu.
University of Illinois Chicago · USUniversity of Michigan · USIndiana University Bloomington · US

Funding

Strategies and Functional Outcomes of Enhancing in Vivo Production of Soluble Rage IsoformsR01DK109948 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HAUS, JACOB M · 2016 to 2020
$3.1M
Alternate day fasting for weight loss, weight maintenance, and cardio-protectionR01HL106228 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI VARADY, KRISTA AMY · 2011 to 2014
$1.5M
Research-Reporting Fidelity within Dietary Weight-Loss Supplement Scientific LiteratureF32DK107157 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KROEGER, CYNTHIA M. · 2015 to 2017
$149k
NHLBI NIH HHS R01 HL106228NIDDK NIH HHS F32 DK107157NIDDK NIH HHS R01 DK109948
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe receptor for advanced glycation end products (RAGE) is implicated in obesogenesis. Conversely, soluble RAGE (sRAGE) competitively inhibits RAGE. Our aim was to determine the effects of weight-loss via alternate day fasting (ADF) on sRAGE isoforms and evaluate potential relationships with body composition. METHODS AND

results42 obese participants were randomized to control (CON) or ADF. For 24 weeks, the ADF group consumed 25% or 125% of their caloric requirements on alternating days while the CON group did not change their diet. Body fat was measured via DXA, visceral fat (VAT) via MRI and subcutaneous fat (SAT) was derived by subtracting VAT from total fat. sRAGE isoforms were measured via ELISAs. After 24 weeks, ADF -6.8 (-9.5, -3.5)kg (Median, IQR) lost more weight than CON -0.3 (-1.9, 1.0)kg (p < 0.05). The change in endogenous secretory RAGE (esRAGE) was different between ADF 15 (-30, 78)pg/mL and CON -21 (-72, 16)pg/mL after 24 weeks (p < 0.05). To examine the effect of changes in body composition, the cohort was stratified by median weight-, fat-, SAT-, and VAT-loss. The changes in all sRAGE isoforms were different between those above and below median weight-loss (p < 0.05) with sRAGE isoforms tending to decrease in individuals below the median. Changes in total sRAGE and esRAGE were different between individuals above compared to below median fat- and SAT-loss (p < 0.05). Those above median fat-loss increased esRAGE by 29 (-5, 66)pg/mL (p < 0.05).

conclusionImprovements in body composition are related to increased sRAGE isoforms, implicating sRAGE as a potential target for the treatment of obesity. CLINICAL

trial registrationNCT00960505.

Indexed as

AdiposityFastingWeight LossAbsorptiometry, PhotonAdipocytesAdultBiomarkersChicagoEnergy IntakeEnzyme-Linked Immunosorbent AssayFemaleHumansIntra-Abdominal FatMagnetic Resonance ImagingMaleMiddle AgedAGER protein, humanBiomarkersReceptor for Advanced Glycation End ProductsAdipokinesAlternate day fastingInflammationObesitySoluble RAGE

Identifiers

PMID30297199
PMCPMC6231965
OpenAlexW2886669554

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.